Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Ritu Salani, MD, MBA
Susana Campos, MD, MPH
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Rana McKay, MD
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
Tanya Dorff, MD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Sandy Srinivas, MD
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Nicoletta Colombo, MD
Advancing Prostate Cancer Care: Integrating Guideline Updates and Patient Preferences for Optimal ADT Management of Advanced Prostate Cancer
Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.